NCT04951050 (T-P) is a NA clinical trial of Rapamycin target eluting stent in Coronary Artery Disease, sponsored by Shanghai MicroPort Medical (Group) Co., Ltd..

Who is sponsoring NCT04951050?

NCT04951050 is sponsored by Shanghai MicroPort Medical (Group) Co., Ltd..

What drugs are being tested in NCT04951050?

Interventions in NCT04951050: Rapamycin target eluting stent.

What condition does NCT04951050 study?

NCT04951050 studies Coronary Artery Disease, Coronary Stenosis.

Is NCT04951050 still recruiting?

NCT04951050 is currently active, enrolled. Last updated 9 November 2023.

Last reviewed 2023-11-09 · How we verify

NCT04951050: T-P

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TARGET-PREMIER Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in CAS Treatment

Active, enrolled NA Last updated 9 November 2023

What this trial tests

NA trial testing Rapamycin target eluting stent in Coronary Artery Disease in 200 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

28 February 2022

Primary endpoint
26 August 2023

31 December 2027

Quick facts

Lead sponsor	Shanghai MicroPort Medical (Group) Co., Ltd.
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	28 February 2022
Primary completion	26 August 2023
Estimated completion	31 December 2027
Sites	1 location across China

Drugs / interventions tested

Rapamycin target eluting stent

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →
Coronary Stenosis — all drugs for Coronary Stenosis →

Sponsor

Shanghai MicroPort Medical (Group) Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Coronary Artery Disease or Coronary Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the TARGET PREMIER trail in to demonstrate the safety and efficacy of the rapamycin target eluting stent in the treatment of subjects with ischemic heart disease (asymptomatic myocardial ischemia , table or unstable angina), with target lesion(s) in coronary arteries with visually estimated reference vessel diameter ≥2.25mm and ≤4.0 mm.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Signaling pathways and targeted therapy for myocardial infarction.
Zhang Q, Wang L, Wang S, Cheng H, et al · · 2022 · cited 525× · PMID 35273164 · DOI 10.1038/s41392-022-00925-z

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other Shanghai MicroPort Medical (Group) Co., Ltd. trials

Trials by the same sponsor.

NCT04479722 — Using Left Atrium Appendage Closure in NVAF Patients With High Risk of Ischemic Stroke · NA · active not recruiting
NCT04918615 — Compare Sirolimus Coated Balloon Catheter With Paclitaxel Coated Balloon Catheter in De Novo Coronary Bifurcated Lesions · NA · unknown
NCT04562532 — Firehawk Rapamycin Target Eluting Coronary Stent North American Trial · NA · active not recruiting
NCT04538001 — Safety and Efficacy of Rotator Cuff Function Restoration Balloon in Irreparable Rotator Cuff Tear · NA · unknown
NCT04386213 — Trial for MicroPort's DCB · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04951050 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai MicroPort Medical (Group) Co., Ltd.
Last refreshed: 9 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04951050.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing